ALFA Filings
Every announcement, straight from the exchange
Every Anthem Biosciences earnings call announcement on NSE and BSE, newest first, each with its own page.
Time
6 announcements with these filters
Revenue fell 25% YoY due to deferred deliveries, though management claims a record order book will drive second-half recovery. While EBITDA margins remain high at 39.6%, the quarter reflects high lumpiness in the CRDMO business.
Anthem reported Q1FY27 revenue of ₹4,182 Mn with a 39.6% EBITDA margin. Results reflect timing shifts in deliveries, though management reports strong underlying demand and year-on-year margin improvement.
Anthem Biosciences delivered record Q4 performance with FY26 revenue of ₹2,280cr and 43.4% EBITDA margins, driven by CRDMO strength.
Anthem delivered robust FY26 growth, overcoming destocking challenges in their core CRDMO segment.
Anthem Biosciences achieved record Q4FY26 revenue of ₹6,109 Mn. The company delivered 15.2% FY26 revenue growth with strong EBITDA margins of 43.4% driven by its CRDMO segment.
Anthem Biosciences delivered a high-growth Q1 FY26, leveraging its commercialized molecule portfolio and strong cash position. Management is balancing aggressive capacity expansion with optimistic 20% long-term growth aspirations despite near-term lumpiness.